Bank of America Issues Positive Forecast for Candel Therapeutics (NASDAQ:CADL) Stock Price

Posted by Brian Himes on Aug 14th, 2026

Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective hoisted by equities researchers at Bank of America from $9.00 to $12.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s price objective suggests a potential upside of 2.04% from the stock’s current price.

Several other analysts have also commented on the company. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Cantor Fitzgerald assumed coverage on Candel Therapeutics in a research note on Monday, April 20th. They set an “overweight” rating for the company. HC Wainwright reissued a “buy” rating and set a $23.00 price objective on shares of Candel Therapeutics in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Friday, July 17th. Finally, Stifel Nicolaus assumed coverage on shares of Candel Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.29.

Get Our Latest Stock Report on CADL

Candel Therapeutics Price Performance

NASDAQ:CADL traded down $0.04 during mid-day trading on Friday, hitting $11.76. The company’s stock had a trading volume of 1,358,791 shares, compared to its average volume of 1,527,929. The company has a market capitalization of $861.66 million, a price-to-earnings ratio of -11.98 and a beta of -0.51. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $11.93. The stock has a fifty day moving average of $9.62 and a 200-day moving average of $7.37.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.25). As a group, equities analysts forecast that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity at Candel Therapeutics

In other news, insider Francesca Barone sold 23,447 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider owned 77,362 shares in the company, valued at approximately $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the completion of the sale, the chief technology officer owned 83,865 shares of the company’s stock, valued at approximately $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Candel Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. bought a new position in shares of Candel Therapeutics in the first quarter worth about $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Candel Therapeutics by 37.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after purchasing an additional 4,583 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Candel Therapeutics by 26.8% in the first quarter. Rhumbline Advisers now owns 33,302 shares of the company’s stock valued at $188,000 after purchasing an additional 7,030 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Candel Therapeutics by 31.5% in the second quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock valued at $4,575,000 after purchasing an additional 216,509 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Candel Therapeutics by 36.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company’s stock worth $99,000 after purchasing an additional 5,270 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

More Candel Therapeutics News

Here are the key news stories impacting Candel Therapeutics this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $23 price target, implying substantial upside from the stock’s recent level near $11.63. The firm expects Candel to become profitable in future years, forecasting EPS of $0.69 in fiscal 2028 and $1.41 in fiscal 2029. Benzinga analyst rating article
Positive Sentiment: Candel continues to target a biologics license application submission in the fourth quarter for its prostate cancer candidate, with management highlighting meaningful execution toward the filing. The company is also aiming for its first commercial product in 2027, providing a potential catalyst if regulatory milestones remain on schedule. CADL commercial product and BLA article
Neutral Sentiment: The company provided second-quarter 2026 financial results and a corporate update as investors assess its development timeline, financing needs, and progress toward commercialization. Candel Therapeutics second-quarter results
Negative Sentiment: Candel reported a quarterly loss of $0.52 per share, substantially worse than the consensus loss estimate of $0.27. The company remains unprofitable, with analysts expecting a full-year loss of $0.91 per share. Candel earnings press release
Negative Sentiment: HC Wainwright modestly reduced its long-term EPS forecasts, cutting fiscal 2028 expectations from $0.71 to $0.69 and fiscal 2029 expectations from $1.45 to $1.41. Although the firm remains bullish, the revisions signal slightly lower anticipated profitability.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.